The Deal Aims to Strengthen the Luxury Skincare Brand’s Growth Across International Markets
Luxury skincare brand Cible Skin has secured a significant minority investment from Verlinvest. Financial details of the deal remain undisclosed.
The investment aims to propel the growth of Cible Skin across various markets, including Europe, China, the U.S., and South America. It also seeks to facilitate the development of new products and treatments based on the brand’s patented immune-cosmetic approach.
Cible Skin was founded by Raphaël Aknin, a pharmaceutical doctor, and Jean Ginefri, an entrepreneur, in 2015. It positions itself as a luxury skincare brand utilizing the science of cell immunity rejuvenation for optimal results. Aknin’s research on skin immunity, particularly in the context of cancer, has been instrumental in shaping the brand’s approach.
The brand’s product line includes 12 face care products formulated with natural, clean active ingredients. These products underwent extensive development over five years, involving analysis of data from 6,000 faces by a scientific committee chaired by Aknin.
Cible Skin’s patented approach focuses on bolstering skin cells’ immune system to protect, regenerate, and repair the skin, resulting in anti-aging and ultra-moisturizing effects. All formulations are developed in-house by Aknin and his team.
Since its launch, Cible Skin has experienced rapid sales growth and operates an exclusive flagship clinic, La Maison Cible Skin, in Paris. The brand’s products are sold online and in its flagship store, with plans for expansion into France’s pharmacy channel.
Verlinvest, founded in 1995, focuses on investments in consumer goods, health, consumer technology, and lifestyle sectors. Its portfolio includes companies such as Oatly, Purplle.com, Tony’s Chocolonely, and Clone, among others.